BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24285017)

  • 21. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
    Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
    J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
    Jourdan E; Richard B
    Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
    Ott MG; Marmé F; Moldenhauer G; Lindhofer H; Hennig M; Spannagl R; Essing MM; Linke R; Seimetz D
    Int J Cancer; 2012 May; 130(9):2195-203. PubMed ID: 21702044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
    Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
    Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
    Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic and immunologic therapies for ovarian cancer.
    Berek JS; Schultes BC; Nicodemus CF
    J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.
    Larson TA; Hu M; Janik JE; Nussenblatt RB; Morris JC; Sen HN
    Ocul Immunol Inflamm; 2012 Aug; 20(4):312-4. PubMed ID: 22642512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
    Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinantly engineered human proteins: transforming the treatment of psoriasis.
    Gottlieb AB; Bos JD
    Clin Immunol; 2002 Nov; 105(2):105-16. PubMed ID: 12482385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunology - development of novel anti-cancer therapies.
    Rothschild SI; Thommen DS; Moersig W; Müller P; Zippelius A
    Swiss Med Wkly; 2015; 145():w14066. PubMed ID: 25668078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abagovomab for ovarian cancer.
    Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
    Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.